Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives.

Götz MR, Collado JA, Fernández-Ruiz J, Fiebich BL, García-Toscano L, Gómez-Cañas M, Koch O, Leha A, Muñoz E, Navarrete C, Pazos MR, Holzgrabe U.

Front Pharmacol. 2019 Nov 20;10:1284. doi: 10.3389/fphar.2019.01284. eCollection 2019.

2.

Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy.

Pretzsch CM, Voinescu B, Lythgoe D, Horder J, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, Edden RAE, Williams S, Murphy DGM, Daly E, McAlonan GM.

Transl Psychiatry. 2019 Nov 20;9(1):313. doi: 10.1038/s41398-019-0654-8.

3.

Phytochemical and Ecological Analysis of Two Varieties of Hemp (Cannabis sativa L.) Grown in a Mountain Environment of Italian Alps.

Pavlovic R, Panseri S, Giupponi L, Leoni V, Citti C, Cattaneo C, Cavaletto M, Giorgi A.

Front Plant Sci. 2019 Oct 15;10:1265. doi: 10.3389/fpls.2019.01265. eCollection 2019.

4.

Potency Analysis of Medical Marijuana Products from New York State.

Li L, Duffy BC, Durocher LA, Dittmar MA, Acosta RA, Delaney ER, Li L, Aldous KM, Spink DC.

Cannabis Cannabinoid Res. 2019 Sep 23;4(3):195-203. doi: 10.1089/can.2018.0037. eCollection 2019.

5.

The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients.

Pagano E, Romano B, Iannotti FA, Parisi OA, D'Armiento M, Pignatiello S, Coretti L, Lucafò M, Venneri T, Stocco G, Lembo F, Orlando P, Capasso R, Di Marzo V, Izzo AA, Borrelli F.

Pharmacol Res. 2019 Nov;149:104464. doi: 10.1016/j.phrs.2019.104464. Epub 2019 Sep 22.

PMID:
31553934
6.

Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.

Zamberletti E, Gabaglio M, Woolley-Roberts M, Bingham S, Rubino T, Parolaro D.

Front Cell Neurosci. 2019 Aug 9;13:367. doi: 10.3389/fncel.2019.00367. eCollection 2019.

7.

Analysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analog.

Citti C, Linciano P, Forni F, Vandelli MA, Gigli G, Laganà A, Cannazza G.

J Pharm Biomed Anal. 2019 Oct 25;175:112752. doi: 10.1016/j.jpba.2019.06.049. Epub 2019 Jul 12.

PMID:
31330283
8.

Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice.

Zamberletti E, Gabaglio M, Piscitelli F, Brodie JS, Woolley-Roberts M, Barbiero I, Tramarin M, Binelli G, Landsberger N, Kilstrup-Nielsen C, Rubino T, Di Marzo V, Parolaro D.

J Psychopharmacol. 2019 Jul;33(7):894-907. doi: 10.1177/0269881119844184. Epub 2019 May 14.

PMID:
31084246
9.

O-Methyl Phytocannabinoids: Semi-synthesis, Analysis in Cannabis Flowerheads, and Biological Activity.

Caprioglio D, Allegrone G, Pollastro F, Valera S, Lopatriello A, Collado JA, Munoz E, Appendino G, Taglialatela-Scafati O.

Planta Med. 2019 Aug;85(11-12):981-986. doi: 10.1055/a-0883-5383. Epub 2019 Apr 1.

PMID:
30934093
10.

Decarbonylation: A metabolic pathway of cannabidiol in humans.

Kraemer M, Broecker S, Madea B, Hess C.

Drug Test Anal. 2019 Jul;11(7):957-967. doi: 10.1002/dta.2572. Epub 2019 Mar 20.

PMID:
30698361
11.

Preclinical safety and efficacy of cannabidivarin for early life seizures.

Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA.

Neuropharmacology. 2019 Apr;148:189-198. doi: 10.1016/j.neuropharm.2019.01.002. Epub 2019 Jan 10.

PMID:
30633929
12.

Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients.

Roslawski MJ, Remmel RP, Karanam A, Leppik IE, Marino SE, Birnbaum AK.

Ther Drug Monit. 2019 Jun;41(3):357-370. doi: 10.1097/FTD.0000000000000583.

PMID:
30520828
13.

Investigational small molecules in phase II clinical trials for the treatment of epilepsy.

Greco M, Varriale G, Coppola G, Operto F, Verrotti A, Iezzi ML.

Expert Opin Investig Drugs. 2018 Dec;27(12):971-979. doi: 10.1080/13543784.2018.1543398. Epub 2018 Nov 13. Review.

PMID:
30408428
14.

Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development.

Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, White HS.

Epilepsia. 2018 Oct;59(10):1842-1866. doi: 10.1111/epi.14555. Erratum in: Epilepsia. 2019 Jan;60(1):187.

15.

Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells.

Russo C, Ferk F, Mišík M, Ropek N, Nersesyan A, Mejri D, Holzmann K, Lavorgna M, Isidori M, Knasmüller S.

Arch Toxicol. 2019 Jan;93(1):179-188. doi: 10.1007/s00204-018-2322-9. Epub 2018 Oct 19.

16.

Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.

Iannotti FA, Pagano E, Moriello AS, Alvino FG, Sorrentino NC, D'Orsi L, Gazzerro E, Capasso R, De Leonibus E, De Petrocellis L, Di Marzo V.

Br J Pharmacol. 2019 May;176(10):1568-1584. doi: 10.1111/bph.14460. Epub 2018 Sep 9.

PMID:
30074247
17.

Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome.

Vigli D, Cosentino L, Raggi C, Laviola G, Woolley-Roberts M, De Filippis B.

Neuropharmacology. 2018 Sep 15;140:121-129. doi: 10.1016/j.neuropharm.2018.07.029. Epub 2018 Jul 27.

PMID:
30056123
18.

Investigational cannabinoids in seizure disorders, what have we learned thus far?

Ružić Zečević D, Folić M, Tantoush Z, Radovanović M, Babić G, Janković SM.

Expert Opin Investig Drugs. 2018 Jun;27(6):535-541. doi: 10.1080/13543784.2018.1482275. Epub 2018 Jun 6. Review.

PMID:
29842819
19.

Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis.

Petrosino S, Verde R, Vaia M, Allarà M, Iuvone T, Di Marzo V.

J Pharmacol Exp Ther. 2018 Jun;365(3):652-663. doi: 10.1124/jpet.117.244368. Epub 2018 Apr 9.

PMID:
29632236
20.

Cannabinoids for epilepsy: What do we know and where do we go?

Brodie MJ, Ben-Menachem E.

Epilepsia. 2018 Feb;59(2):291-296. doi: 10.1111/epi.13973. Epub 2017 Dec 6. Review.

Supplemental Content

Loading ...
Support Center